

**Pharmacy and Therapeutics Committee  
Meeting of February 1, 2005  
Kellogg Center, Michigan State University  
6 PM  
MEETING MINUTES**

**Welcome and Introductions:**

The meeting was called to order at 6:10PM by Richard Slaughter, Chair. In attendance were Rob Ernst, MD, Richard Slaughter, MSc., D. Eggleston, MD, D. VanLoo, PharmD., and G. Perri, MD from the Committee. Also attending were G. Baker, MD, A. Paul, RPh., L. Jackson, PharmD., D. Quillan, Pharmacy Analyst  
Committee members absent were: J. Henry MD, J. Fiechtner, MD, M. Robins, DO, and R. Coffey, PharmD.

**Public Comment:**

Greg Warren, and Dr. K. Patel, Wyeth, Altace®  
John Valenti, and J. Gandhi, Sanofi, Avalide®, Avapro®  
Allen Goldberg, MD, Merck, Cozaar®, Hyzaar®  
Pinakin Attawalla, MD, Schering Plough, Vytorin®  
Thomas Constance PharmD, Novartis, Lotrel®  
John Presutti, President, Presutti Labs, Tindamax®  
James Cwengros, PharmD, Pfizer, Norvasc®  
Earl Crosby, Boehringer, Micardis®  
Lisa Mena, Teamm Pharma, Xodol®

**Review and Approval of Minutes of December 7, 2004 Meeting**

The minutes of the December 7, 2004 meeting were approved.

**New Drug Reviews**

**Factive®.** The Committee voted to recommend this drug be added to the Preferred Drug List (PDL) with prior authorization.

**Sanctura®.** The Committee voted to recommend this drug be added to the Preferred Drug List (PDL) with prior authorization.

**Tindamax®.** The Committee voted to recommend this drug be added to the MPPL with no prior authorization.

**Vytorin®.** The Committee voted to recommend this drug be added to the MPPL. It will be added to the Statins class on the PDL, with prior authorization. However, if the patient is already prescribed Zetia®, a clinical edit would allow a prescription for Vytorin® without prior authorization. This determination, however, is contingent on First Health's and the Department's analysis of cost effectiveness. Xifaxan. The Committee voted to recommend this drug be added to the MPPL with no prior authorization.

**Tarceva®.** The Committee voted to recommend this drug be added to the MPPL with no prior authorization.

Extensions. The following pharmaceuticals were reviewed as Line Extensions:

Product	Generic Name	PDL Class? Y/N	Recommendation
Flextra	ACETAMINOPHN/P-TLOX CI/CAFFEIN	Y	Non-covered
Durabac	Sal-amide/APAP/P-tlox/Caff	N	Non-covered
Dispermox 600 mg	Amoxicillin dispertab	N	cover
Dolgit Plus	APAP/Caffeine, Butalb.	N	cover
Estrasorb	estradiol gel	N	cover
Mirtazapine 7.5 mg	Mirtazapine 7.5 mg	N	cover
Floxin Otic singles	Ofloxacin	N	cover
Alcortin gel	HC/Aloe/Iodoquinol	N	cover
Estragel 0.06%	estradiol get	N	cover
Levacet	ASA/Sal-amide/APAP/Caff	N	cover
Panlor SS	DHCodeine/APAP/Caff	Y (analgesics)	Non-prefer
Panixine dispertab	cephalexin dispertab	Y (cephalosporins)	cover
Fortamet ER	metformin OSM	Y (Biguanides)	Non-prefer
Methylin chew tabs and oral suspension	methylphenidate chewable and oral suspension	Y(ADHD-ADD)	Non-prefer
Xodol	Hydrocodone/APAP	Y (analgesics)	Non-prefer
Quinapril & Quinapril HCTZ	Quinapril & Quinapril HCTZ	Y	Non-prefer
Clindess 2% vag	Clindamycin Phosphate	N	cover
Lamical tab starter kit	Lamotrigine	N	cover
Restoril 22.5 mg cap	Temazepam	Y	cover, PA > 65 yrs
Evoclin 1% foam	Clindamycin Phosphate	N	cover
Clarinet Syrup	Desloratadine	Y	Non-prefer

### PDL Review

Discussion occurred following a presentation by Dr. Ernst.

**Angiotension Converting Enzyme Inhibitors** No changes were recommended to this PDL class.

**Angiotension Receptor Antagonists** No changes were recommended to this PDL class.

**Calcium Channel Blockers** No changes were recommended to this PDL class.

**Therapeutic Controversies** – R. Slaughter, MSc., went over a system to classify and evaluate fixed dose combination drugs. The Committee discussed and voted to make this a guideline to follow when reviewing these products.

### Key Questions

The committee reviewed worksheets on the following classes:

Miscellaneous Categories on PDL, Scheduled for April 2005 Meeting

Glaucoma treatments, Osteoporosis treatments, Serotonin Receptor Agonists, Urinary Tract

Antispasmodics, Oral sexual Dysfunction Drugs, Topical Immunomodulators

Cardiac Beta blockers, 2 group, Lipotropics, Beta blockers, scheduled for April meeting.

The next meeting is scheduled for **Tuesday April 5, 2005 – 6PM.**